Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 5 | 2019 | 257 | 1.240 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 430 | 1.240 |
Why?
|
| Rhabdomyosarcoma | 4 | 2025 | 200 | 1.030 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2023 | 51 | 1.000 |
Why?
|
| Mitotane | 1 | 2024 | 2 | 0.930 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2024 | 9 | 0.920 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2024 | 17 | 0.920 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 37 | 0.840 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 254 | 0.810 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 25 | 0.780 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2022 | 16 | 0.780 |
Why?
|
| MicroRNAs | 3 | 2018 | 827 | 0.760 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 120 | 0.710 |
Why?
|
| Sarcoma, Ewing | 4 | 2023 | 116 | 0.680 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 12 | 0.590 |
Why?
|
| Neoplasms | 6 | 2024 | 2758 | 0.590 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 432 | 0.560 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 98 | 0.540 |
Why?
|
| Sarcoma | 3 | 2025 | 194 | 0.540 |
Why?
|
| Wilms Tumor | 1 | 2018 | 111 | 0.540 |
Why?
|
| Exanthema | 1 | 2017 | 68 | 0.530 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 178 | 0.490 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 1590 | 0.480 |
Why?
|
| Skin | 1 | 2017 | 506 | 0.460 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1680 | 0.440 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 1439 | 0.440 |
Why?
|
| Oncologists | 2 | 2023 | 29 | 0.390 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 1309 | 0.360 |
Why?
|
| Adolescent | 17 | 2025 | 19104 | 0.340 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 1213 | 0.330 |
Why?
|
| Transcriptome | 1 | 2015 | 902 | 0.320 |
Why?
|
| Humans | 30 | 2025 | 123092 | 0.270 |
Why?
|
| Young Adult | 9 | 2024 | 8839 | 0.250 |
Why?
|
| Cyclophosphamide | 3 | 2023 | 422 | 0.250 |
Why?
|
| Child | 15 | 2025 | 24231 | 0.250 |
Why?
|
| Trophoblastic Tumor, Placental Site | 1 | 2024 | 1 | 0.230 |
Why?
|
| Bronchial Neoplasms | 1 | 2024 | 15 | 0.230 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 5 | 0.230 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2024 | 7 | 0.230 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 25 | 0.220 |
Why?
|
| Chilblains | 1 | 2023 | 3 | 0.210 |
Why?
|
| Leuprolide | 1 | 2023 | 25 | 0.210 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 11 | 0.210 |
Why?
|
| Pneumonectomy | 1 | 2024 | 129 | 0.210 |
Why?
|
| Uterine Neoplasms | 1 | 2024 | 118 | 0.200 |
Why?
|
| Patient Participation | 2 | 2023 | 220 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 68 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 165 | 0.200 |
Why?
|
| Female | 15 | 2024 | 65538 | 0.200 |
Why?
|
| Decision Making | 2 | 2024 | 651 | 0.200 |
Why?
|
| Medical Oncology | 1 | 2023 | 214 | 0.190 |
Why?
|
| Molecular Biology | 1 | 2022 | 77 | 0.190 |
Why?
|
| Physicians, Women | 1 | 2021 | 46 | 0.190 |
Why?
|
| Proton Therapy | 1 | 2022 | 123 | 0.180 |
Why?
|
| Doxorubicin | 3 | 2023 | 299 | 0.180 |
Why?
|
| Legislation, Drug | 1 | 2020 | 9 | 0.180 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.180 |
Why?
|
| Career Choice | 1 | 2021 | 144 | 0.180 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 439 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 130 | 0.170 |
Why?
|
| Fertility Preservation | 1 | 2020 | 61 | 0.160 |
Why?
|
| Prognosis | 3 | 2018 | 4513 | 0.160 |
Why?
|
| Genomics | 3 | 2024 | 1475 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2023 | 1162 | 0.160 |
Why?
|
| Epigenomics | 1 | 2019 | 162 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2022 | 527 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 254 | 0.150 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.140 |
Why?
|
| Male | 11 | 2024 | 60091 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 85 | 0.140 |
Why?
|
| Parents | 1 | 2024 | 1031 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1118 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1084 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 641 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 510 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 715 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 151 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 186 | 0.110 |
Why?
|
| Allografts | 1 | 2015 | 190 | 0.110 |
Why?
|
| ROC Curve | 1 | 2015 | 555 | 0.110 |
Why?
|
| Child, Preschool | 4 | 2024 | 13884 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 208 | 0.100 |
Why?
|
| Adult | 7 | 2024 | 29018 | 0.100 |
Why?
|
| Vincristine | 2 | 2023 | 196 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1877 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 653 | 0.090 |
Why?
|
| Survival Rate | 3 | 2024 | 1997 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1872 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2014 | 513 | 0.080 |
Why?
|
| Etoposide | 2 | 2023 | 117 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1142 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3665 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2826 | 0.080 |
Why?
|
| Infant | 3 | 2018 | 12357 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3720 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16037 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5047 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 887 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4285 | 0.060 |
Why?
|
| Mice | 3 | 2017 | 17541 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8111 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 859 | 0.060 |
Why?
|
| Europe | 1 | 2025 | 350 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 400 | 0.060 |
Why?
|
| Survivorship | 1 | 2023 | 36 | 0.050 |
Why?
|
| Cysts | 1 | 2024 | 100 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 24 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2025 | 376 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 37 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1232 | 0.050 |
Why?
|
| Aneurysm, False | 1 | 2024 | 102 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 61 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 91 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3370 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 185 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2022 | 55 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 219 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 606 | 0.050 |
Why?
|
| United States | 3 | 2021 | 10645 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1004 | 0.050 |
Why?
|
| Pregnancy | 2 | 2024 | 7162 | 0.050 |
Why?
|
| Ovary | 1 | 2024 | 389 | 0.050 |
Why?
|
| Government Regulation | 1 | 2020 | 42 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 345 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2024 | 378 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 148 | 0.040 |
Why?
|
| Animals | 3 | 2017 | 33794 | 0.040 |
Why?
|
| Placenta | 1 | 2024 | 493 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 1781 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 10013 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 826 | 0.040 |
Why?
|
| Fertility | 1 | 2020 | 263 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 996 | 0.040 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 31 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 69 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 106 | 0.040 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 286 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 216 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 571 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2055 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 480 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 1061 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 101 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 330 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 6 | 0.030 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 228 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1461 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 19092 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 151 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 75 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2015 | 149 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 42 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 229 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 121 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 831 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 332 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 155 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 757 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 534 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1929 | 0.030 |
Why?
|
| Cisplatin | 1 | 2014 | 242 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 862 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2022 | 3316 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 638 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 846 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2307 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2395 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12119 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4356 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 5772 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 4490 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 25993 | 0.010 |
Why?
|